FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3028587039> ?p ?o ?g. }

• W3028587039 abstract "Following treatment with androgen receptor (AR) pathway inhibitors, ~20% of prostate cancer patients progress by shedding their dependence on AR. These tumors undergo epigenetic reprogramming turning castration-resistant prostate cancer adenocarcinoma (CRPC-Adeno) into neuroendocrine prostate cancer (CRPC-NEPC). Currently, no targeted therapies are available for CRPC-NEPCs. A major hurdle in the development of new therapies and treatment of CRPC-NEPC is the lack of accurate models to test candidate treatments. Such models would ideally capture components of the tumor microenvironment (TME) factors, which likely regulate the phenotypic, genetic, and epigenetic underpinnings of this aggressive subset. The TME is a complex system comprised not only of malignant prostate cells but also stromal and inflammatory cells and a scaffold of extracellular matrix (ECM). ECM proteins are implicated in the survival and progression of cancer and development of chemoresistance, while are equally integral to the development of prostate cancer organoids. Here, using a combination of patient tumor proteomics and RNA sequencing, we define putative ECM cues that may guide the growth of prostate tumors in patients. Using this molecular information, we developed synthetic hydrogels that recapitulate the tumor ECM. Organoids cultured in the synthetic hydrogel niches demonstrate that ECM subtypes regulate the morphology, transcriptome, and epigenetics hallmarks of CRPC-Adeno and CRPC-NEPC. CRPC-NEPC organoid showed a differential response to small molecule inhibitors of epigenetic repressor EZH2 and Dopamine Receptor D2 (DRD2), the latter being a novel target in CRPC-NEPC when grown in tumor-specific ECM. Finally, in those synthetic ECM niches where drug resistance was observed in CRPC-NEPCs, cellular reprogramming by a synergistic combination of EZH2 inhibitors with DRD2 antagonists inhibited tumor growth. The synthetic platform can provide a more realistic prostate-specific microenvironment and subsequently enable the development of effective targeted therapeutics for prostate cancers." @default.
• W3028587039 created "2020-05-29" @default.
• W3028587039 creator A5007593808 @default.
• W3028587039 creator A5008547275 @default.
• W3028587039 creator A5009003697 @default.
• W3028587039 creator A5025841084 @default.
• W3028587039 creator A5028420362 @default.
• W3028587039 creator A5036851932 @default.
• W3028587039 creator A5042271005 @default.
• W3028587039 creator A5046264445 @default.
• W3028587039 creator A5047882814 @default.
• W3028587039 creator A5056800304 @default.
• W3028587039 creator A5057401496 @default.
• W3028587039 creator A5057570241 @default.
• W3028587039 creator A5061702711 @default.
• W3028587039 creator A5073680918 @default.
• W3028587039 creator A5082844309 @default.
• W3028587039 date "2020-05-20" @default.
• W3028587039 modified "2023-10-18" @default.
• W3028587039 title "Extracellular Microenvironment in Patient-derived Hydrogel Organoids of Prostate Cancer Regulates Therapeutic Response" @default.
• W3028587039 cites W1997423100 @default.
• W3028587039 cites W2005334224 @default.
• W3028587039 cites W2010457001 @default.
• W3028587039 cites W2036213518 @default.
• W3028587039 cites W2039511031 @default.
• W3028587039 cites W2041570722 @default.
• W3028587039 cites W2042261220 @default.
• W3028587039 cites W2042936107 @default.
• W3028587039 cites W2077540512 @default.
• W3028587039 cites W2080752012 @default.
• W3028587039 cites W2100305481 @default.
• W3028587039 cites W2108234281 @default.
• W3028587039 cites W2110534364 @default.
• W3028587039 cites W2111618967 @default.
• W3028587039 cites W2119504728 @default.
• W3028587039 cites W2123507520 @default.
• W3028587039 cites W2124826140 @default.
• W3028587039 cites W2128005590 @default.
• W3028587039 cites W2130410032 @default.
• W3028587039 cites W2134526812 @default.
• W3028587039 cites W2141831115 @default.
• W3028587039 cites W2148643283 @default.
• W3028587039 cites W2154378559 @default.
• W3028587039 cites W2169456326 @default.
• W3028587039 cites W2179438025 @default.
• W3028587039 cites W2214074259 @default.
• W3028587039 cites W2262087934 @default.
• W3028587039 cites W2288055189 @default.
• W3028587039 cites W2302332254 @default.
• W3028587039 cites W2530065228 @default.
• W3028587039 cites W2552754421 @default.
• W3028587039 cites W2571250257 @default.
• W3028587039 cites W2574271406 @default.
• W3028587039 cites W2598884790 @default.
• W3028587039 cites W2611739609 @default.
• W3028587039 cites W2613790813 @default.
• W3028587039 cites W2626802208 @default.
• W3028587039 cites W2749663845 @default.
• W3028587039 cites W2766832099 @default.
• W3028587039 cites W2788051020 @default.
• W3028587039 cites W2797647983 @default.
• W3028587039 cites W2808350668 @default.
• W3028587039 cites W2889646458 @default.
• W3028587039 cites W2890540126 @default.
• W3028587039 cites W2957594695 @default.
• W3028587039 cites W2973864382 @default.
• W3028587039 cites W2989611985 @default.
• W3028587039 cites W2991142728 @default.
• W3028587039 cites W2999012858 @default.
• W3028587039 doi "https://doi.org/10.1101/2020.05.17.20104349" @default.
• W3028587039 hasPublicationYear "2020" @default.
• W3028587039 type Work @default.
• W3028587039 sameAs 3028587039 @default.
• W3028587039 citedByCount "3" @default.
• W3028587039 countsByYear W30285870392021 @default.
• W3028587039 crossrefType "posted-content" @default.
• W3028587039 hasAuthorship W3028587039A5007593808 @default.
• W3028587039 hasAuthorship W3028587039A5008547275 @default.
• W3028587039 hasAuthorship W3028587039A5009003697 @default.
• W3028587039 hasAuthorship W3028587039A5025841084 @default.
• W3028587039 hasAuthorship W3028587039A5028420362 @default.
• W3028587039 hasAuthorship W3028587039A5036851932 @default.
• W3028587039 hasAuthorship W3028587039A5042271005 @default.
• W3028587039 hasAuthorship W3028587039A5046264445 @default.
• W3028587039 hasAuthorship W3028587039A5047882814 @default.
• W3028587039 hasAuthorship W3028587039A5056800304 @default.
• W3028587039 hasAuthorship W3028587039A5057401496 @default.
• W3028587039 hasAuthorship W3028587039A5057570241 @default.
• W3028587039 hasAuthorship W3028587039A5061702711 @default.
• W3028587039 hasAuthorship W3028587039A5073680918 @default.
• W3028587039 hasAuthorship W3028587039A5082844309 @default.
• W3028587039 hasBestOaLocation W30285870391 @default.
• W3028587039 hasConcept C104317684 @default.
• W3028587039 hasConcept C121608353 @default.
• W3028587039 hasConcept C1491633281 @default.
• W3028587039 hasConcept C150194340 @default.
• W3028587039 hasConcept C162317418 @default.
• W3028587039 hasConcept C16930146 @default.
• W3028587039 hasConcept C189165786 @default.
• W3028587039 hasConcept C2776107976 @default.

• next